Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268957
Max Phase: Preclinical
Molecular Formula: C21H19FN4O5S
Molecular Weight: 458.47
Associated Items:
ID: ALA5268957
Max Phase: Preclinical
Molecular Formula: C21H19FN4O5S
Molecular Weight: 458.47
Associated Items:
Canonical SMILES: N#Cc1cc2c(nc1N1CCC(C(=O)NS(=O)(=O)Cc3ccccc3F)CC1)COC2=O
Standard InChI: InChI=1S/C21H19FN4O5S/c22-17-4-2-1-3-14(17)12-32(29,30)25-20(27)13-5-7-26(8-6-13)19-15(10-23)9-16-18(24-19)11-31-21(16)28/h1-4,9,13H,5-8,11-12H2,(H,25,27)
Standard InChI Key: BRRMNXCSPDJKRY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 458.47 | Molecular Weight (Monoisotopic): 458.1060 | AlogP: 1.63 | #Rotatable Bonds: 5 |
Polar Surface Area: 129.46 | Molecular Species: ACID | HBA: 8 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.97 | CX Basic pKa: 0.62 | CX LogP: 1.72 | CX LogD: 0.78 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.67 | Np Likeness Score: -1.44 |
1. Kong D, Xue T, Guo B, Cheng J, Liu S, Wei J, Lu Z, Liu H, Gong G, Lan T, Hu W, Hu W, Yang Y.. (2019) Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties., 62 (6.0): [PMID:30843696] [10.1021/acs.jmedchem.8b01971] |
Source(1):